---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABTECT-1"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABTECT-1. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 87 evidence topics quoted from 20 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abtect-1"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABTECT-1

<a id="heading-3.1.1"></a>

## 3.1.1 ABTECT-1

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.1-2"></a>

#### Primary objectives for the FDA and for the EMA in the protocol

> “The primary/co-primary and key secondary efficacy endpoints will be analyzed separately for FDA and National Regulatory Authorities other than EMA.”
> “For the FDA and National Regulatory Authorities other than EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on clinical remission defined as:”
> “For the EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.1-3"></a>

#### Place of the trial in the phase 3 development plan

> “This study is part of a phase 3 clinical development program comprising two similar 8-week induction studies (ABX464-105 and ABX464-106), followed by a maintenance study (ABX464-107) to confirm the efficacy and safety of obefazimod in the short and long-term treatment of moderate to severely active UC in adults and adolescents from 16 to 18 years of age.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.1-4"></a>

#### Main objective in the EU Clinical Trials Information System record

> “Main objective To compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”

Source: [EU Clinical Trials Information System 2022-500535-36-01](https://euclinicaltrials.eu/ctis-public/view/2022-500535-36-01)

<a id="topic-3.1.1.1-5"></a>

#### Aim stated in the late-breaking abstract

> “Here we report efficacy and safety of two Phase 3, 8‐week, induction trials in adult pts with UC from ABTECT‐1 [ NCT05507203 ] and ABTECT‐2 [ NCT05507216 ].”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-11-16”
> “Primary Completion (Actual) 2025-06-24”
> “Study Completion (Actual) 2025-06-25”
> “First Posted 2022-08-18”
> “Results First Posted 2026-09-10”
> “Last Update Posted 2026-09-10”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 264 locations”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.2-3"></a>

#### Planned number of sites and potential countries in the protocol

> “Approximately 350 sites located worldwide will participate in the study.”
> “(List of potential countries: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, China, Czech Republic, France, Germany, Greece, Hungary, India, Italy, Korea, Netherlands, Poland, Portugal, Spain, Switzerland, Turkey, UK, Ukraine, USA)”
> “Recruitment period: Q3 2022 Q4 2024 (approx. 26 months)”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.2-4"></a>

#### Sites and countries of the two induction trials stated by the company

> “ABTECT-1 and ABTECT-2 were conducted simultaneously and have enrolled 1,275 patients from over 600 participating clinical trial sites in 36 countries with the intent to satisfy regulatory requirements globally.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.1.2-5"></a>

#### Start of the phase 3 trials and first U.S. enrollment

> “We initiated our pivotal Phase 3 clinical trials of obefazimod for the treatment of moderately to severely active UC in October 2022, which consists of two induction trials (ABTECT-1 and ABTECT-2) and one ABTECT maintenance trial.”
> “Enrollment of the first patient under this program in the United States occurred on October 11, 2022.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.1.2-6"></a>

#### EU member states and trial dates in the EU Clinical Trials Information System record

> “Locations Netherlands, Poland, Austria, Italy, Germany, Spain, Greece, France, Portugal, Czechia, Hungary, Bulgaria, Belgium”
> “Start of trial 12/06/2023 End of trial 25/06/2025 Global end of trial 25/06/2025”

Source: [EU Clinical Trials Information System 2022-500535-36-01](https://euclinicaltrials.eu/ctis-public/view/2022-500535-36-01)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Design in the ClinicalTrials.gov record

> “Official Title A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Evaluate the Efficacy and Safety of ABX464 Once Daily for Induction Treatment in Subjects With Moderately to Severely Active Ulcerative Colitis”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Triple”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.3-2"></a>

#### Periods, randomization ratio, and planned arm sizes in the protocol

> “This induction study is a multicenter, randomized, placebo-controlled study to evaluate the efficacy and safety of obefazimod given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response (lack of response, loss of response, or intolerance) to either conventional therapies and/or advanced therapies.”
> “As shown below, this study consists of a screening period of up to 4 weeks, an 8-week induction period followed by 4-week follow up period.”
> “On Day 1, eligible subjects will be randomized and allocated into three treatment arms according to ratio 1:1:2 as follows: Placebo: 153 subjects Obefazimod Daily dose 25 mg QD: 153 subjects Obefazimod Daily dose 50 mg QD: 306 subjects”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-3"></a>

#### Randomization stratification factors

> “Randomization will be stratified according to the following factors: Subjects with inadequate response to advanced therapies [AT-IR subjects] (lack of response, loss of response or intolerance to advanced therapies (Yes/No) Subjects with concomitant oral corticosteroids at baseline (Yes/No)”
> “Previous discontinuation of an advance therapy for any reason other than inadequate response, e.g., pregnancy, economic reasons or termination of a clinical trial, will not be considered as AT-IR.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-4"></a>

#### Endoscopy, central reading, and electronic diaries

> “During the screening period, a full colonoscopy will be performed for all subjects unless one has been performed within the last 3 months before screening.”
> “At Week 8, only a flexible sigmoidoscopy is required.”
> “Endoscopies will be centrally read.”
> “Biopsies will be centrally analyzed.”
> “e-Diaries will be used to collect stool frequency, rectal bleedings, nocturnal bowel movements, bowel urgency and fatigue NRS on a daily basis, as well as whether the subjects took the study treatment and the intake time.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-5"></a>

#### Independent central review of video-recorded endoscopies stated by the company

> “Each of the trials were randomized, double-blind and placebo-controlled, using independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at the end of the 44-week maintenance trial (total 52 weeks), as recommended by the FDA.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.1.3-6"></a>

#### Entry into the maintenance trial after Week 8

> “In the randomized double-blind placebo-controlled study part [Part 1; placebo, obefazimod 25 mg, obefazimod 50 mg] for clinical responders at Week 8.”
> “In the double-blind multi-arm study part [Part 2; obefazimod 25 mg or obefazimod 50 mg] for non-clinical responders at Week 8.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-7"></a>

#### Rationale for the doses and the 8-week treatment duration in the protocol

> “The ABX464-103 phase 2b UC study has demonstrated that the 25 mg dose was also efficacious for induction with a safety profile comparable to placebo (except transient headaches generally reported during the first several days of treatment).”
> “The 100 mg dose showed similar efficacy to the 25 and 50 mg doses but with a higher incidence of most frequently reported TEAEs and was not selected for this”
> “After 16 weeks of treatment there were a limited number of patients who achieved a clinical response that was not observed at Week 8. Therefore, it is reasonable to define 8 weeks as the treatment duration for the induction study.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.3-8"></a>

#### Design stated in the late-breaking abstract

> “Pts were randomized 2:1:1 to Obe 50 mg QD (Obe‐50), Obe 25 mg QD (Obe‐25) or placebo (PBO) for 8 weeks.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Key inclusion criteria in the ClinicalTrials.gov record

> “Men or women at least 16 years old; Adolescent subjects will only be enrolled if approved by the country regulatory/health authority.”
> “Documented diagnosis of UC confirmed by endoscopy and histology.”
> “Active disease defined by modified Mayo score (MMS) ≥ 5 with rectal bleeding subscore (RBS) ≥ 1 and endoscopy subscore (MES) of 2 or 3 (confirmed by central reader).”
> “Subjects with documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids, immunosuppressant, biologic or biosimilar therapies, S1P receptor modulators and/or JAK inhibitors and/or new drugs approved during the study (note: failure to only 5-ASA or sulfasalazine is not accepted).”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.4-2"></a>

#### Key exclusion criteria in the ClinicalTrials.gov record

> “Subjects with UC limited to an isolated proctitis (≤ 15cm from anal verge) determined by endoscopy central reading.”
> “Subjects with primary sclerosing cholangitis or autoimmune hepatitis.”
> “Subjects on antidiarrheals including those working on motility (e.g., loperamide, diphenoxylate with atropine, etc.).”
> “Creatinine clearance < 60 mL.min-1 (Cockroft-Gault formula)”
> “Subjects with HIV infection.”
> “Subjects with a family or personal history of congenital or acquired long QT syndrome, or subjects with a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval [Fridericia or Bazett correction] >450 milliseconds for male and > 460 milliseconds for female).”
> “Subjects previously treated with ABX464.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.4-3"></a>

#### Minimum age by region in the protocol

> “Male or female (at birth) at least 16 years old, except in European Union (EU)/European Economic Area (EEA) and Ukraine, where subjects must be at least 18 years old at the time of eligibility assessment.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.4-4"></a>

#### Definition of inadequate response to JAK inhibitors in the protocol

> “Inadequate response to JAK inhibitors (tofacitinib, filgotinib, upadacitinib) is defined as: i. Lack of response to an induction course; ii. Loss of response or recurrence of symptoms during maintenance course following primary response after induction course (discontinuation despite clinical benefit does not qualify); iii. Intolerance to JAK inhibitor treatment including (but not limited to) increase of serious infection, malignancies, deep venous thrombosis (DVT), or major adverse cardiac event (MACE).”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.4-5"></a>

#### Eligibility summarized in the late-breaking abstract

> “The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Arms and administration in the ClinicalTrials.gov record

| Arm | Description in the record |
| --- | --- |
| ABX464 50 mg | “Experimental: ABX464 50mg Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks” |
| ABX464 25 mg | “Experimental: ABX464 25mg Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks” |
| Placebo | “Placebo Comparator: Placebo Subjects will be orally dosed daily in a fed condition ideally at the same time in the morning) for 8 weeks” |
| Intervention | “Administered once daily in the morning with food” |
| Other name of ABX464 | “Obefazimod” |

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.5-2"></a>

#### Capsule strengths and dosing instructions in the protocol

> “Depending on the treatment arm allocation, obefazimod or its matching placebo (capsules) 50 mg and 25 mg are administered once daily in a fed condition (ideally at the same time in the morning) for 8 weeks during the induction phase.”
> “25 mg regimen: 1 capsule of obefazimod 25 mg per day”
> “50 mg regimen: 1 capsule of obefazimod 50 mg per day”
> “1 capsule of placebo per day”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.5-3"></a>

#### Background ulcerative colitis therapy allowed during the trial

> “For the treatment of UC (provided stable dose for at least 2 weeks prior to the screening endoscopy and during the whole induction study), the following medications are allowed upon entry into the study:”
> “Oral 5-ASA.”
> “At study entry, subjects randomized to any treatment group may continue certain background therapy for UC (e.g., 5-aminosalicylic acid [5-ASA] compounds and/or oral CS); therefore, even subjects randomized to the placebo treatment during the treatment period will have concomitant therapies that may be partially effective at controlling UC symptoms.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.5-4"></a>

#### Doses and route stated by the company

> “The ABTECT-1 and ABTECT-2 induction trials are global, multicenter, randomized, double-blind, placebo-controlled trials assessing once-daily oral administration of obefazimod at 25 mg or 50 mg doses in adult patients with moderately to severely active UC.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Primary endpoint and its definition in the ClinicalTrials.gov record

> “Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8”
> “Clinical remission is defined as stool frequency subscore (SFS) = 0 or 1 and rectal bleeding subscore (RBS) = 0, and Mayo Endoscopic Score (MES) = 0 or 1 (MES of 1 modified to exclude friability).”
> “Modified Mayo score is a composite measure of ulcerative disease activity consisting of three components: stool frequency, rectal bleeding and endoscopic subscores. Each component is scored from 0 (normal or inactive disease) to 3 (severe activity). The total range score ranges from 0 to 9, with higher scores indicating more severe disease activity.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.6.1-2"></a>

##### FDA recommendation of clinical remission by the modified Mayo Score as the primary endpoint

> “We recommend evaluating the proportion of subjects achieving clinical remission as the”
> “Clinical remission: Defined as an mMS score of 0 to 2, including the following three”
> “Stool frequency subscore = 0 or 1”
> “Rectal bleeding subscore = 0”
> “Centrally read endoscopy subscore = 0 or 1 (score of 1 modified to”
> “exclude friability)”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.1.6.1-3"></a>

##### Reason the physician global assessment is excluded from the modified Mayo Score

> “The mMS is a composite endpoint consisting of rectal bleeding, stool frequency, and endoscopy subscores, adapted from the originally published Mayo Score. The previously used physician global assessment component is excluded to reduce subjectivity and focus the evaluation on the subject’s directly reported symptoms and directly observable endoscopic findings.”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.1.6.1-4"></a>

##### FDA recommendations on entry criteria and central reading of endoscopy

> “Subjects should have a score of 5 to 9 on the modified Mayo Score (mMS),”
> “including an endoscopy subscore of at least 2.”
> “We recommend using centralized reading of endoscopies as the primary approach”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.1.6.1-5"></a>

##### Company statement that the endpoint and entry criteria follow FDA guidance

> “The inclusion criteria based on FDA guidance for moderately to severely active UC is active disease defined by a Modified Mayo Score ≥ 5 with (RBS) ≥ 1 and endoscopy subscore of 2 or 3 (confirmed by central reader).”
> “The primary endpoint for induction and maintenance is clinical remission defined as SFS of 0 or 1 and not greater than baseline and RBS = 0 and endoscopy subscore of 0 or 1.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.1.6.1-6"></a>

##### Co-primary endpoints for the EMA: endoscopic improvement and symptomatic remission

> “For the EMA purposes, the primary efficacy objective is to compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission. The co-primary endpoints are defined as: o Proportion of subjects who achieve endoscopic improvement at Week 8 o Proportion of subjects with symptomatic remission at Week 8.”
> “Symptomatic remission is defined as SFS = 0 or 1 and RBS = 0.”
> “Endoscopic improvement is defined as MES = 0 or 1 (MES of 1 modified to exclude friability).”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.6.1-7"></a>

##### Key secondary endpoints for the FDA

> “For the FDA and National Regulatory Authorities other than EMA, the key secondary efficacy objectives and endpoints are: To compare the efficacy of obefazimod versus placebo on endoscopic improvement. o Proportion of subjects who achieve endoscopic improvement at Week 8. To compare the efficacy of obefazimod versus placebo on clinical response o Proportion of subjects with clinical response at Week 8. To compare the efficacy of obefazimod versus placebo on HEMI. o Proportion of subjects with HEMI per Geboes scoring at Week 8.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.6.1-8"></a>

##### Secondary endpoint definitions in the ClinicalTrials.gov record

> “Clinical Response is defined as a reduction from baseline in MMS ≥ 2 points and a relative reduction from baseline in MMS ≥ 30%, and a reduction from baseline in Rectal Bleeding Score (RBS) ≥ 1 point and/or RBS = 0 or 1.”
> “HEMI is defined as endoscopic improvement associated with histologic improvement per Geboes score.”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.6.1-9"></a>

##### Patient-reported and other secondary endpoints in the protocol

> “To compare the efficacy of obefazimod versus placebo on Bowel Urgency (BU). o Proportion of subjects with BU = 0 by visit in the subpopulation of subjects with BU at baseline.”
> “To compare the efficacy of obefazimod versus placebo on FACIT-Fatigue questionnaire. o Change from baseline in the FACIT-Fatigue at Week 8.”
> “To compare the efficacy of obefazimod versus placebo on IBDQ. o Change from Baseline in IBDQ total score and domain subscores at Week 8.”
> “To compare the efficacy of obefazimod versus placebo on EQ-5D-5L. o Change from baseline in EQ-5D-5L score by visit.”
> “To compare the efficacy of obefazimod versus placebo in WPAI. o Change from baseline in WPAI:UC score at Week 8.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.6.1-10"></a>

##### Status of symptomatic remission under each regulatory protocol in the late-breaking abstract

> “Symptomatic remission was an “other secondary” endpoint, not multiplicity controlled, for the FDA protocol.”
> “Endoscopic improvement/symptomatic remission were co‐primary endpoints for the EMA protocol and were met by both doses in both trials.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Planned sample size in the protocol

> “Approximately 612 subjects will be randomized in this study.”
> “A total of 612 subjects (153:153:306) will allow the detection of a difference of at least”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 639”

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants analyzed by arm in the posted results

| Population | ABX464 50 mg | ABX464 25 mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Started | “318” | “161” | “160” | Not reported |
| Baseline (Full Analysis Set) | “318” | “160” | “158” | “636” |
| Primary and secondary endpoints (Full Analysis Set) | “318” | “160” | “158” | Not reported |
| Adverse events (at risk) | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” | Not reported |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants randomized and treated in the late-breaking abstract

> “1272 pts were randomized and treated in ABTECT‐1 (636) and ABTECT‐2 (636).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.7.1-5"></a>

##### Participants randomized across both induction trials stated by the company

> “Overall, 1,275 patients were randomized and 1,272 patients were treated in ABTECT-1 (N=636) and ABTECT-2 (N=636).”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Full Analysis Set and participants randomized but not dosed

> “The Full Analysis Set includes all randomized participants who received at least one dose of study drug. One participant in the ABX464 25 mg group and 2 in the placebo group were randomized but did not receive any dose of study drug.”

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.7.2-2"></a>

##### Analysis sets in the statistical analysis plan

> “The Randomized Set includes all subjects who were randomized to study treatment.”
> “The FAS includes all randomized subjects who received at least one dose of study drug. Subjects will be analyzed according to the treatment group to which they were randomized (i.e., “as randomized”), regardless of the treatment received. The efficacy analysis will be based on the FAS.”
> “The Safety Set includes all randomized subjects who have received at least one dose of study drug. Subjects will be analyzed according to the treatment received (i.e., “as treated”).”

Source: [Abivax ABX464-105 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/SAP_001.pdf)

<a id="topic-3.1.1.7.2-3"></a>

##### Primary analysis method and testing sequence in the protocol

> “will be analyzed using a Cochran Mantel Haenszel test (CMH) test adjusting for AT-IR (yes/no) and baseline oral corticosteroid treatment (yes/no) as stratification factors, using the Full Analysis Set (FAS).”
> “If comparisons on primary endpoints for each dose are statistically significant, then, the testing procedure will continue through each of the key secondary endpoints in the prespecified order until an endpoint fails to reach statistical significance, after which all subsequent key secondary endpoints will be considered exploratory.”
> “Interim analysis: No interim analysis is planned.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.7.2-4"></a>

##### Handling of intercurrent events and missing data in the statistical analysis plan

> “The Composite Strategy will be applied for each of the above IEs for the main analyses of all primary and key secondary estimands.”
> “For the supplementary analysis of all primary and key secondary estimands, a Treatment Policy approach will be applied for the above three IEs.”
> “In the main analysis of all binary responder-type endpoints, subjects with missing data, regardless of reason for missingness, will be considered as non-responders.”

Source: [Abivax ABX464-105 statistical analysis plan (2025)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/SAP_001.pdf)

<a id="topic-3.1.1.7.2-5"></a>

##### Testing hierarchy and pooled analysis in the late-breaking abstract

> “Hierarchical testing strategy was used starting with 50 mg for the primary endpoint followed by the key secondary endpoints; the 25 mg was subsequently tested for the primary endpoint followed by the key secondary endpoints.”
> “NRI is used for subjects with missing outcome at week 8 and subjects reporting any IE prior to week 8. % Difference is for Obe minus placebo and is based on estimated common risk difference using the Mantel‐Haenszel weights adjusting for the randomization stratification factors: inadequate response to advanced therapies (yes/no), baseline oral corticosteroids usage (yes/no), and region (Japan/rest of world) [ABTECT‐2 only].”
> “for pooled analysis, all p ‐values are nominal.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Participant flow by arm in the posted results

| Disposition | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Started | “318” | “161” | “160” |
| Completed | “291” | “155” | “143” |
| Not completed | “27” | “6” | “17” |
| Adverse event | “18” | “0” | “6” |
| Lost to follow-up | “1” | “1” | “1” |
| Never dosed | “0” | “1” | “1” |
| Non-compliance with study drug | “2” | “0” | “0” |
| Physician decision | “1” | “0” | “1” |
| Protocol violation | “1” | “0” | “1” |
| Withdrawal by subject | “4” | “4” | “7” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.1-2"></a>

##### Participants randomized but never dosed

> “One participant in ABX464 25 mg group was never dosed. Two participants in the placebo group were never dosed: One participant reason recorded for non-completion is "never dosed". One participant reason recorded for non-completion is 'adverse event" (the adverse event occurred before first dose administration).”

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.1-3"></a>

##### Pooled ABTECT-1 and ABTECT-2: study discontinuation and reasons

| Disposition | Obefazimod 50 mg | Obefazimod 25 mg | Placebo |
| --- | --- | --- | --- |
| Participants who discontinued the study, n (%) | “54 (8.5)” | “23 (7.2)” | “31 (9.7)” |
| Adverse event, n (% of discontinuations) | “31 (57.4)” | “8 (34.8)” | “14 (45.2)” |
| Withdrawal by subject | “13 (24.1)” | “10 (43.5)” | “10 (32.3)” |
| Lack of efficacy | “2 (3.7)” | “2 (8.7)” | “1 (3.2)” |
| Lost to follow-up | “4 (7.4)” | “1 (4.3)” | “1 (3.2)” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

> “Percentages are calculated relative to the number of randomized pts (ie, N=636, 320, 319 for Obe-50, Obe-25, PBO, respectively).”

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.1-4"></a>

##### Pooled ABTECT-1 and ABTECT-2: entry into the maintenance trial

> “Among the 1,275 patients randomized in the induction trials, 678 achieved clinical response and enrolled into part 1 of the maintenance trial.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Baseline characteristics by arm in the posted results

| Characteristic | ABX464 50 mg (n=318) | ABX464 25 mg (n=160) | Placebo (n=158) | Total (n=636) |
| --- | --- | --- | --- | --- |
| Age, years, mean (SD) | “42.7(14.3)” | “41.5(13.54)” | “43.1(13.59)” | “42.5(13.93)” |
| Age 65 years or older, participants | “25” | “12” | “11” | “48” |
| Female, participants | “129” | “56” | “66” | “251” |
| Male, participants | “189” | “104” | “92” | “385” |
| Asian, participants | “87” | “34” | “45” | “166” |
| Black or African American, participants | “5” | “3” | “2” | “10” |
| White, participants | “219” | “114” | “106” | “439” |
| Weight, kg, mean (SD) | “72.41(18.581)” | “72.58(17.269)” | “71.28(16.392)” | “72.17(17.713)” |
| Duration of ulcerative colitis, years, mean (SD) | “7.98(7.348)” | “7.8(7.151)” | “7.51(7.761)” | “7.82(7.395)” |
| At least one prior advanced therapy inadequate response, participants | “149” | “70” | “69” | “288” |
| Inadequate response to JAK inhibitors among those with AT-IR, participants | “22” | “15” | “15” | “52” |
| Modified Mayo Score, mean (SD) | “6.9(1.06)” | “6.8(1.04)” | “6.9(1.04)” | “6.9(1.05)” |
| Mayo endoscopic subscore 2, participants | “128” | “69” | “64” | “261” |
| Mayo endoscopic subscore 3, participants | “190” | “91” | “94” | “375” |
| Fecal calprotectin, µg/g, mean (SD) | “3768.46(6219.12)” | “2533.58(3761.06)” | “5390.53(9479.94)” | “3828.77(6729.81)” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.2-2"></a>

##### Proportion with prior advanced therapy inadequate response in the late-breaking abstracts

> “In both trials, baseline demographics and disease characteristics were similar between groups; 45.3% and 49.3% of pts had inadequate response to one or more advanced therapies.”
> “Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.2-3"></a>

##### Pooled ABTECT-1 and ABTECT-2: endoscopic severity and prior JAK inhibitor failure

> “A total of 1272 patients were enrolled across the ABTECT trials, with approximately 60% being classified as having an endoscopic subscore of 3. Of the total pooled population, approximately 47% were classified as having a prior inadequate response to advanced therapy (‘AT-IR Yes’) with approximately 21% having failed to respond to a JAK inhibitor.”

Source: [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect)

<a id="topic-3.1.1.8.2-4"></a>

##### Pooled ABTECT-1 and ABTECT-2: baseline disease extent

> “Among randomized and treated pts in ABTECT trials, 280 presented with proctosigmoiditis, 474 with left-sided colitis, and 497 with extensive colitis.”

Source: [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669)

<a id="topic-3.1.1.8.2-5"></a>

##### Pooled ABTECT-1 and ABTECT-2: baseline disease duration

> “Of the 1272 randomized and treated pts in ABTECT trials, 250 pts had BDD<2, 662 pts had BDD2-10 and 360 pts had a BDD≥10.”
> “Baseline demographics and disease characteristics were overall equivalent between treatment groups, and comparable between BDD groups except a higher proportion of BDD2-10 and BDD≥10 pts having endoscopic score of 3 and prior inadequate response to advanced therapy vs BDD<2 pts.”

Source: [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748)

<a id="topic-3.1.1.8.2-6"></a>

##### Pooled ABTECT-1 and ABTECT-2: treatment exposure

| Exposure | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Duration of exposure, days, mean (SD) | “58.8 (12.62)” | “59.5 (11.14)” | “58.7 (11.14)” |
| Duration of exposure, days, median [min, max] | “60.0 [1, 106]” | “61.0 [4, 96]” | “61.0 [5, 102]” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary and key secondary endpoints at Week 8

| Endpoint at Week 8, % (n) | Placebo (N=158) | Obefazimod 25 mg (N=160) | Obefazimod 50 mg (N=318) | 25 mg minus placebo, % | 25 mg p-value | 50 mg minus placebo, % | 50 mg p-value |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical remission (primary) | “2.5 (4)” | “23.8 (38)” | “21.7 (69)” | “21.4” | “p < 0.0001” | “19.3” | “p < 0.0001” |
| Clinical response | “28.5 (45)” | “65.6 (105)” | “61.0 (194)” | “37.2” | “p < 0.0001” | “32.6” | “p < 0.0001” |
| Endoscopic improvement | “5.7 (9)” | “37.5 (60)” | “33.3 (106)” | “32.0” | “p < 0.0001” | “27.8” | “p < 0.0001” |
| HEMI | “3.2 (5)” | “23.8 (38)” | “23.0 (73)” | “20.7” | “p < 0.0001” | “20.0” | “p < 0.0001” |
| Symptomatic remission | “17.7 (28)” | “42.5 (68)” | “41.2 (131)” | “24.9” | “p < 0.0001” | “23.7” | “p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-2"></a>

##### Participants meeting each endpoint at Week 8 in the posted results

| Endpoint at Week 8, participants | ABX464 50 mg (n=318) | ABX464 25 mg (n=160) | Placebo (n=158) |
| --- | --- | --- | --- |
| Clinical remission per modified Mayo Score (primary) | “69” | “38” | “4” |
| Endoscopic improvement | “106” | “60” | “9” |
| Clinical response per modified Mayo Score | “194” | “105” | “45” |
| HEMI per Geboes | “73” | “38” | “5” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.3-3"></a>

##### Primary endpoint result stated by the company

> “Individually, ABTECT-1 showed a placebo-adjusted clinical remission rate of 19.3% (p<0.0001) and ABTECT-2 demonstrated 13.4% (p=0.0001), each at the 50 mg once-daily dose, with all key secondary efficacy endpoints being met.”
> “The 25 mg once-daily dose of obefazimod achieved the FDA primary endpoint of clinical remission at Week 8 in ABTECT-1 demonstrating a placebo-adjusted remission rate of 21.4%.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.1.8.3-4"></a>

##### Pooled ABTECT-1 and ABTECT-2: primary and secondary endpoints at Week 8

| Endpoint at Week 8, % (n) | Placebo (N=317) | Obefazimod 25 mg (N=319) | Obefazimod 50 mg (N=636) | 25 mg minus placebo, % | 50 mg minus placebo, % |
| --- | --- | --- | --- | --- | --- |
| Clinical remission | “4.4 (14)” | “17.6 (56)” | “20.8 (132)” | “13.2” | “16.4” |
| Clinical response | “30.9 (98)” | “59.6 (190)” | “62.1 (395)” | “28.6” | “31.2” |
| Endoscopic improvement | “7.9 (25)” | “29.8 (95)” | “34.4 (219)” | “21.9” | “26.6” |
| HEMI | “5.4 (17)” | “18.5 (59)” | “23.4 (149)” | “13.2” | “18.2” |
| Symptomatic remission | “19.9 (63)” | “37.9 (121)” | “40.7 (259)” | “18.1” | “21.0” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

> “In a pooled analysis, both Obe‐50 and Obe‐25 met all primary and secondary endpoints with nominal significance ( p < 0.0001) (Table 1).”
> “for pooled analysis, all p ‐values are nominal.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-5"></a>

##### Pooled ABTECT-1 and ABTECT-2: early symptomatic improvement from Week 1

> “In a pooled analysis of the Phase 3 ABTECT-1 and ABTECT-2 induction trials, both Obe-50mg and Obe-25mg produced reductions in rectal bleeding subscores and stool frequency subscores versus PBO starting from week 1 and reaching a nominally significant difference by week 2 (p-value <0.05)”
> “A greater proportion of patients receiving obefazimod (50mg or 25mg) versus PBO achieved symptomatic response from week 1 and symptomatic remission from week 2 increasing through week 8”

Source: [Abivax press release, ECCO 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-evidence-anti-fibrotic-activity-obefazimod)

<a id="topic-3.1.1.8.3-6"></a>

##### Pooled presentation of both trials: miR-124 expression and serum IL-17A and IL-6 at Week 8

> “In both Phase 3 ABTECT induction trials, Obe-25mg and Obe-50mg significantly enhanced expression of miR-124 in blood (unadjusted p < 0.0001 vs. PBO) and in rectal and sigmoidal tissue (unadjusted p < 0.0001 vs. PBO) at week 8”
> “At week 8, Obe-25mg and Obe-50mg significantly reduced IL-17A levels in serum (unadjusted p < 0.0001 vs. PBO); Obe-25mg (p=0.0150 vs. PBO) and Obe-50mg (p=0.0039 vs. PBO) decreased IL-6 levels in serum”

Source: [Abivax press release, ECCO 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-first-evidence-anti-fibrotic-activity-obefazimod)

<a id="topic-3.1.1.8.3-7"></a>

##### Subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)

| Endpoint at Week 8, % (n) | AT-IR-Yes placebo (N=69) | AT-IR-Yes 25 mg (N=70) | AT-IR-Yes 50 mg (N=149) | AT-IR-No placebo (N=89) | AT-IR-No 25 mg (N=90) | AT-IR-No 50 mg (N=169) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission | “1.4 (1)” | “8.6 (6)” | “14.1 (21)” | “3.4 (3)” | “35.6 (32)” | “28.4 (48)” |
| Endoscopic improvement | “4.3 (3)” | “14.3 (10)” | “22.1 (33)” | “6.7 (6)” | “55.6 (50)” | “43.2 (73)” |
| Symptomatic remission | “10.1 (7)” | “27.1 (19)” | “34.9 (52)” | “23.6 (21)” | “54.4 (49)” | “46.7 (79)” |
| HEMI | “1.4 (1)” | “5.7 (4)” | “12.8 (19)” | “4.5 (4)” | “37.8 (34)” | “32.0 (54)” |
| Clinical response | “21.7 (15)” | “52.9 (37)” | “54.4 (81)” | “33.7 (30)” | “75.6 (68)” | “66.9 (113)” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

| Placebo-adjusted difference at Week 8, % and nominal p-value | AT-IR-Yes 25 mg | AT-IR-Yes 50 mg | AT-IR-No 25 mg | AT-IR-No 50 mg |
| --- | --- | --- | --- | --- |
| Clinical remission | “7.1 p = 0.0556” | “12.7 p = 0.0039” | “32.4 p < 0.0001” | “25.0 p < 0.0001” |
| Endoscopic improvement | “9.9 p = 0.0457” | “17.8 p = 0.0011” | “48.9 p < 0.0001” | “36.4 p < 0.0001” |
| Symptomatic remission | “17.0 p = 0.0108” | “25.0 p = 0.0001” | “31.0 p < 0.0001” | “23.2 p = 0.0003” |
| HEMI | “4.3 p = 0.1803” | “11.3 p = 0.0073” | “33.4 p < 0.0001” | “27.5 p < 0.0001” |
| Clinical response | “31.2 p = 0.0002” | “32.5 p < 0.0001” | “41.8 p < 0.0001” | “33.2 p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-8"></a>

##### Pooled ABTECT-1 and ABTECT-2: subgroups by prior advanced therapy inadequate response at Week 8 (nominal p-values)

| Endpoint at Week 8, % (n) | AT-IR-Yes placebo (N=148) | AT-IR-Yes 25 mg (N=146) | AT-IR-Yes 50 mg (N=308) | AT-IR-No placebo (N=169) | AT-IR-No 25 mg (N=173) | AT-IR-No 50 mg (N=328) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission | “3.4 (5)” | “6.8 (10)” | “13.3 (41)” | “5.3 (9)” | “26.6 (46)” | “27.7 (91)” |
| Endoscopic improvement | “6.8 (10)” | “13.0 (19)” | “24.4 (75)” | “8.9 (15)” | “43.9 (76)” | “43.9 (144)” |
| Symptomatic remission | “12.8 (19)” | “26.7 (39)” | “36.0 (111)” | “26.0 (44)” | “47.4 (82)” | “45.1 (148)” |
| HEMI | “4.1 (6)” | “6.8 (10)” | “14.9 (46)” | “6.5 (11)” | “28.3 (49)” | “31.4 (103)” |
| Clinical response | “20.9 (31)” | “46.6 (68)” | “55.8 (172)” | “39.6 (67)” | “70.5 (122)” | “68.0 (223)” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

| Placebo-adjusted difference at Week 8, % and nominal p-value | AT-IR-Yes 25 mg | AT-IR-Yes 50 mg | AT-IR-No 25 mg | AT-IR-No 50 mg |
| --- | --- | --- | --- | --- |
| Clinical remission | “3.5 p = 0.1728” | “10.1 p = 0.0009” | “21.3 p < 0.0001” | “22.4 p < 0.0001” |
| Endoscopic improvement | “6.4 p = 0.0687” | “17.8 p < 0.0001” | “34.9 p < 0.0001” | “34.9 p < 0.0001” |
| Symptomatic remission | “13.8 p = 0.0031” | “23.4 p < 0.0001” | “21.3 p < 0.0001” | “19.2 p < 0.0001” |
| HEMI | “2.9 p = 0.2785” | “11.1 p = 0.0005” | “21.7 p < 0.0001” | “24.7 p < 0.0001” |
| Clinical response | “25.6 p < 0.0001” | “34.9 p < 0.0001” | “30.7 p < 0.0001” | “28.2 p < 0.0001” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-9"></a>

##### Pooled ABTECT-1 and ABTECT-2: clinical response by prior JAK inhibitor failure and number of failed advanced therapies (nominal p-values)

| Subset of AT-IR participants | Placebo, % (n/N) | Obefazimod 25 mg, % (n/N) | 25 mg minus placebo, % and p-value | Obefazimod 50 mg, % (n/N) | 50 mg minus placebo, % and p-value |
| --- | --- | --- | --- | --- | --- |
| Prior JAK inhibitor failure | “20.0 (7/35)” | “47.1 (16/34)” | “27.0 p = 0.0196” | “54.5 (30/55)” | “34.4 p = 0.0017” |
| 1 advanced therapy failure | “24.2 (15/62)” | “53.3 (24/45)” | “30.5 p = 0.0018” | “50.7 (76/150)” | “25.3 p = 0.0008” |
| 2 advanced therapy failures | “20.6 (7/34)” | “48.9 (22/45)” | “28.6 p = 0.0114” | “67.2 (43/64)” | “45.5 p < 0.0001” |
| 3 advanced therapy failures | “14.3 (4/28)” | “42.4 (14/33)” | “27.3 p = 0.0297” | “61.5 (32/52)” | “46.3 p < 0.0001” |
| 4 or more advanced therapy failures | “20.8 (5/24)” | “34.8 (8/23)” | “14.4 p = 0.2968” | “50.0 (21/42)” | “28.7 p = 0.0242” |

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

> “In the AT‐IR‐No subgroup, Obe‐50 and Obe‐25 performed similarly in the pooled analysis across efficacy measures.”
> “The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.3-10"></a>

##### Pooled ABTECT-1 and ABTECT-2: definition of inadequate response to advanced therapies in the subgroup analysis

> “ABTECT-1&2 pooled analysis; all p-values are nominal; AT-IR was defined as inadequate response, loss of response, or intolerance to advanced therapies including biologics, JAK inhibitors, and S1P modulators”

Source: [Abivax press release, UEG late-breaking AT-IR subgroup data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect)

<a id="topic-3.1.1.8.3-11"></a>

##### Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease extent (post hoc, nominal p-values)

> “For this post-hoc analysis, pts were categorized by baseline disease extent as designated by investigator: proctosigmoiditis, left-sided colitis, or extensive colitis.”
> “In the pooled analysis, greater proportions of pts treated with Obe-25 and Obe-50 versus PBO achieved clinical remission in pts with proctosigmoiditis (Obe-25-PBO difference: 16.1%, p = 0.0009; Obe-50-PBO difference: 19.5%, p < 0.0001) and left-sided colitis (Obe-25-PBO difference: 21.1%, p < 0.0001; Obe-50-PBO difference: 23.6%, p < 0.0001), and met all other evaluated efficacy endpoints with nominal significance (Table).”
> “In pts with extensive colitis at baseline, greater proportions of pts treated with Obe-50 versus PBO achieved clinical response, symptomatic response/remission, endoscopic improvement, and HEMI with nominal significance.”

Source: [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669)

<a id="topic-3.1.1.8.3-12"></a>

##### Pooled ABTECT-1 and ABTECT-2: clinical remission by baseline disease duration (post hoc, nominal p-values)

> “In a pooled analysis, a higher proportion of pts receiving Obe-25 or Obe-50 versus PBO achieved clinical remission across BDD subgroups (Obe-50-PBO difference: BDD<2: 20.6%; BDD2-10: 17.8%; BDD≥10: 12.5%; Obe-25-PBO difference: BDD<2: 13.6%; BDD2-10: 13.2%; BDD≥10: 13.0%) and met most endpoints across BDD subgroups with nominal significance (Table).”
> “A numerical trend of greater efficacy with shorter disease duration was observed.”

Source: [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

##### Pooled ABTECT-1 and ABTECT-2: bowel urgency, nocturnal bowel movements, and fatigue at Week 8

> “Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25mg once-daily obefazimod.”
> “At week 8 in the ABTECT 1 & 2 trials, 37% of patients taking once daily 50mg obefazimod reported no bowel urgency (BU) compared to 18.1% of patients in the placebo group”
> “47.6% of patients on 50mg obefazimod reported no nocturnal bowel movements (NBM) at week 8 compared to 24.7% in the placebo group”
> “In the 50 mg group 17.1% of patients reported fatigue remission as measured with the Fatigue Numerical Rating Scale (NRS) at week 8, compared to 7.7% in the placebo group”

Source: [Abivax press release, patient-reported outcomes from ABTECT induction (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-patient-reported-outcomes-data-phase-3-abtect)

<a id="topic-3.1.1.8.4-2"></a>

##### Pooled ABTECT-1 and ABTECT-2: disease-specific and overall quality of life (IBDQ and EQ-5D-5L)

> “The IBDQ has four domains, scores range 32-224; higher scores=better QoL. Meaningful within patient change (MWPC) for IBDQ total score was defined as ≥ 16 point change and remission as ≥ 170 points.”
> “All p-values are nominal.”
> “1272 pts were randomized and treated in ABTECT-1 (n = 636) and ABTECT-2 (n = 636); 1207 had IBDQ, 1137 had EQ-5D-5L Index and 1,180 had EQ-5D-5L VAS data at baseline.”
> “At baseline, pts had mean IBDQ total scores of 110.8, 110.8, and 109.7 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher mean IBDQ scores vs PBO: 161.9, 159.2, and 135.7 in the Obe-50, Obe-25 and PBO groups respectively (Obe-50:Δ25.97 and Obe-25:Δ22.33, p < 0.0001).”
> “At Week 8, a greater proportion of Obe-treated pts had a MWPC: 60.9% for Obe-50 and 56.9% for Obe-25 vs 39.8% for PBO (Obe-50:Δ21.20 and Obe-25:Δ17.07, p < 0.0001). More Obe-treated pts without IBDQ remission at baseline achieved IBDQ remission: 36.7% for Obe-50 and 33.2% for Obe-25 vs 19.6% for PBO (Obe-50:Δ17.13 and Obe-25:Δ13.56, p < 0.001).”
> “At baseline, mean EQ-5D-5L Index scores were 0.66, 0.64, and 0.63 for Obe-50, Obe-25, and PBO, respectively. At Week 8, Obe-treated pts reported higher EQ-5D-5L Index scores vs PBO: mean 0.82, 0.81, and 0.71 in the Obe-50, Obe-25 and PBO groups, respectively (Obe-50:Δ0.10 and Obe-25:Δ0.09, p < 0.0001).”
> “At Week 8, a greater proportion of Obe-treated pts had a MWPC on the EQ-5D-5L Index: 41.0% for Obe-50 and 38.9% for Obe-25 vs 28.5% for PBO (Obe-50:Δ12.59 and Obe-25:Δ10.36, p < 0.01).”

Source: [Baert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.098/8432840)

<a id="topic-3.1.1.8.4-3"></a>

##### Pooled ABTECT-1 and ABTECT-2: work productivity and activity impairment (WPAI:UC)

> “All p values are nominal.”
> “At baseline, 1272 pts were randomized and treated in ABTECT-1 (n = 636) and ABTECT-2 (n = 636); 1153 pts had WPAI:UC data.”
> “At week 8, a smaller proportion of pts treated with Obe reported overall work impairment compared to PBO: 36.2% of Obe-50 pts and 34.6% of Obe-25 pts vs 47.8% of PBO pts (Obe-50: Δ-11.03, Obe-25: Δ-13.21, both p = 0.0002).”
> “At week 8, greater proportions of pts treated with Obe reported a MWPC on overall work impairment relative to PBO: 66.3% for Obe-50 and 71.8% for Obe-25 vs 56.9% of PBO (Obe-50: Δ9.64, p = 0.06; Obe-25: Δ15.13, p < 0.05).”

Source: [Tilg et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.1109/8434071)

Additional sources: [Abivax press release, DDW 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-present-data-obefazimod-digestive-disease-weekr)

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Treatment-emergent adverse events at Week 8 reported by the company

| Event, n (%) | Placebo (N=158) | Obefazimod 25 mg (N=160) | Obefazimod 50 mg (N=318) |
| --- | --- | --- | --- |
| Any TEAE | “84 (53.2%)” | “75 (46.9%)” | “189 (59.4%)” |
| TEAE leading to study drug discontinuation | “6 (3.8%)” | “0 (0.0%)” | “17 (5.3%)” |
| Serious TEAE | “3 (1.9%)” | “1 (0.6%)” | “14 (4.4%)” |
| Malignancy | “0 (0.0%)” | “0 (0.0%)” | “1 (0.3%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “1 (0.6%)” | “1 (0.6%)” | “2 (0.6%)” |

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.1.8.5-2"></a>

##### Serious adverse events, all-cause mortality, and adverse event time frame in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/318 (0.00%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Any serious adverse event | “14/318 (4.40%)” | “1/160 (0.63%)” | “3/158 (1.90%)” |
| Myocardial infarction | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis acute | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Pancreatitis | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Colitis ulcerative | “3/318 (0.94%)” | “0/160 (0.00%)” | “2/158 (1.27%)” |
| Pneumonia | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |
| Appendicitis | “0/318 (0.00%)” | “1/160 (0.63%)” | “0/158 (0.00%)” |
| Prostate cancer stage I | “1/318 (0.31%)” | “0/160 (0.00%)” | “0/158 (0.00%)” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

> “Adverse Events Time Frame up to 12 weeks”
> “Adverse events reported here are treatment emergent adverse events”

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.5-3"></a>

##### Non-serious adverse events at a 5% reporting threshold in the posted results

| Event, affected/at risk (%) | ABX464 50 mg | ABX464 25 mg | Placebo |
| --- | --- | --- | --- |
| Any non-serious adverse event at 5% threshold | “90/318 (28.30%)” | “34/160 (21.25%)” | “28/158 (17.72%)” |
| Headache | “66/318 (20.75%)” | “25/160 (15.63%)” | “9/158 (5.70%)” |
| Nausea | “18/318 (5.66%)” | “5/160 (3.13%)” | “1/158 (0.63%)” |
| Anaemia | “10/318 (3.14%)” | “6/160 (3.75%)” | “9/158 (5.70%)” |
| Colitis ulcerative | “6/318 (1.89%)” | “0/160 (0.00%)” | “8/158 (5.06%)” |
| Arthralgia | “8/318 (2.52%)” | “1/160 (0.63%)” | “8/158 (5.06%)” |

Source: [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results)

<a id="topic-3.1.1.8.5-4"></a>

##### Adverse events in the late-breaking abstract

> “Proportions of pts who reported at least one TEAE in ABTECT‐1 were 59.4%, 46.9%, and 53.2% for Obe‐50, Obe‐25, and PBO, respectively.”
> “The most frequent TEAE was headache (Obe‐50: 20.8%–25.8%; Obe‐25: 14.5%–15.6%; PBO: 5.7).”
> “The headaches were mild, transient, short in duration and not a barrier to treat as evidenced by a low discontinuation rate of 0%–1.6%. No signal was observed for serious, severe, or opportunistic infections or malignancies.”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-3.1.1.8.5-5"></a>

##### Pooled ABTECT-1 and ABTECT-2: integrated summary of treatment-emergent adverse events

| Event, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Any TEAE | “383 (60.2)” | “156 (48.9)” | “161 (50.8)” |
| TEAE related to study drug | “226 (35.5)” | “86 (27)” | “55 (17.4)” |
| TEAE leading to study discontinuation | “30 (4.7)” | “6 (1.9)” | “13 (4.1)” |
| Serious TEAE | “20 (3.1)” | “7 (2.2)” | “10 (3.2)” |
| Malignancies | “1 (0.2)” | “0” | “0” |
| Serious, severe, or opportunistic infections | “4 (0.6)” | “1 (0.3)” | “1 (0.3)” |
| Headache | “148 (23.3)” | “48 (15.0)” | “18 (5.7)” |
| Nausea | “46 (7.2)” | “16 (5.0)” | “4 (1.3)” |
| Abdominal pain | “24 (3.8)” | “2 (0.6)” | “2 (0.6)” |
| Lipase increased | “27 (4.2)” | “9 (2.8)” | “7 (2.2)” |
| Time to onset of first headache, days, median | “1.0” | “1.0” | “7.0” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

> “Prostate cancer stage I in a patient who received obefazimod for two weeks.”
> “the only opportunistic infection was aspergillosis in a placebo patient.”
> “To date, no safety signals have been observed related to either elevations in lipase or more specifically to pancreatitis.”

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.5-6"></a>

##### Pooled ABTECT-1 and ABTECT-2: adverse events leading to study drug discontinuation

| Event, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Ulcerative colitis | “7 (1.1)” | “2 (0.6)” | “7 (2.2)” |
| Headache | “7 (1.1)” | “1 (0.3)” | “0” |
| Vomiting | “4 (0.6)” | “1 (0.3)” | “0” |
| Nausea | “3 (0.5)” | “1 (0.3)” | “0” |
| Pancreatitis acute | “2 (0.3)” | “1 (0.3)” | “1 (0.3)” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.5-7"></a>

##### Pooled ABTECT-1 and ABTECT-2: infection-related adverse events

| Infection, n (%) | Obefazimod 50 mg (n=636) | Obefazimod 25 mg (n=319) | Placebo (n=317) |
| --- | --- | --- | --- |
| Nasopharyngitis | “14 (2.2)” | “9 (2.8)” | “10 (3.2)” |
| Upper respiratory tract infection | “7 (1.1)” | “3 (0.9)” | “6 (1.9)” |
| COVID-19 | “6 (0.9)” | “4 (1.3)” | “1 (0.3)” |
| Influenza | “6 (0.9)” | “3 (0.9)” | “1 (0.3)” |
| Urinary tract infection | “5 (0.8)” | “2 (0.6)” | “0” |
| Pneumonia | “4 (0.6)” | “0” | “1 (0.3)” |

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

> “Rates of infection-related TEAEs among pts were very low, generally below 1% (Table 2). There was no signal for serious, severe, or opportunistic infections or malignancies in the ABTECT induction trials (Table 3).”

Source: [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf)

<a id="topic-3.1.1.8.5-8"></a>

##### Pooled ABTECT-1 and ABTECT-2: integrated safety abstract

> “Overall, 636 patients received Obe-50, 319 received Obe-25, and 317 received placebo (PBO).”
> “The most frequent TEAEs (≥ 3% in obe treated pts and greater than PBO) included headache, nausea, abdominal pain, and an increase in serum lipase. Headache TEAEs were mild, transient, short in duration (median: 2-3 days) and rarely led to discontinuation (0-1.1%). Serious, severe, or opportunistic infections or malignancies were rarely reported.”

Source: [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392)

<a id="topic-3.1.1.8.5-9"></a>

##### Pooled ABTECT-1 and ABTECT-2: headache and nausea rates reported at UEG Week 2025

> “In the pooled full data set across ABTECT 1 & 2, no signal for serious, severe, or opportunistic infections or malignancies was observed. The most commonly reported TEAEs were headache (6%-placebo, 16%-25mg, 24.1%-50mg) with <1% of headaches leading to study discontinuation (0.3% at 25mg; 1.1% at 50mg), and nausea (1.3% in placebo, 5.0% at 25mg, 7.2% at 50mg).”

Source: [Abivax press release, UEG late-breaking safety data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial)

<a id="topic-3.1.1.8.5-10"></a>

##### Headache: most frequent adverse event in the ABTECT induction trials

> “The most frequent TEAE was headache (obefazimod 50 mg: 20.8-25.8%; obefazimod 25 mg: 14.5-15.6%; placebo: 5.7%).”
> “The headaches were mild, transient, short in duration and not a barrier to treatment, as evidenced by a low discontinuation rate of 1.6%.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “The most commonly reported TEAEs were headache (6%-placebo, 16%-25mg, 24.1%-50mg) with <1% of headaches leading to study discontinuation (0.3% at 25mg; 1.1% at 50mg), and nausea (1.3% in placebo, 5.0% at 25mg, 7.2% at 50mg).”

Source: [Abivax press release, UEG late-breaking safety data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial)

> “Headache TEAEs were mild, transient, short in duration (median: 2-3 days) and rarely led to discontinuation (0-1.1%).”

Source: [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392)

<a id="topic-3.1.1.8.5-11"></a>

##### Integrated safety of the ABTECT induction trials

> “Overall, 636 patients received Obe-50, 319 received Obe-25, and 317 received placebo (PBO).”
> “Proportions of pts who reported at least one TEAE were 60.2%, 48.9%, and 50.8% for Obe-50, Obe-25, and PBO, respectively.”
> “The overall rates of serious TEAEs for pts were comparable across groups (Obe-50: 3.1%; Obe-25: 2.2%; PBO: 3.2%).”
> “TEAEs leading to study discontinuation occurred at similar rates across treatment groups (Obe-50, 4.7%; Obe-25, 1.9%; PBO, 4.1%).”
> “The most frequent TEAEs (≥ 3% in obe treated pts and greater than PBO) included headache, nausea, abdominal pain, and an increase in serum lipase.”
> “Serious, severe, or opportunistic infections or malignancies were rarely reported.”

Source: [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392)

<a id="topic-3.1.1.8.5-12"></a>

##### Adverse events of special interest in the phase 3 protocol

> “Headaches are frequently reported by subjects treated with obefazimod.”
> “The headache lasts more than 72 hours continuously (or is an intermittent headache with a continuous symptom free period < 12 hours) and is not relieved by painkillers for > 12 hours.”
> “Anemia will be reported as AESI if hemoglobin < 8 g/dL or if hemoglobin drops > 2 g/dL from baseline.”
> “An increase > 3.0 × ULN in liver transaminases (AST and/or ALT) with or without cholestasis or clinical symptoms”
> “Subjects will be monitored for the development of signs and symptoms of infection during treatment with obefazimod.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="topic-3.1.1.8.5-13"></a>

##### Hepatic enzymes: protocol summary of clinical data

> “Based on nonclinical data, a DILIsym evaluation of obefazimod was conducted and concluded that there was no risk of the drug-induced liver injury (DILI) in these subjects.”
> “Analysis of ALT/AST changes in subjects treated with obefazimod, did not reveal any meaningful variation of the mean ALT/AST measurement throughout treatment nor an increased incidence of any liver function tests (LFTs).”
> “Sporadic cases of isolated alkaline phosphatase increase have been reported in subjects dosed with obefazimod.”

Source: [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: study limitations

- Duration and comparator: ABTECT-1 compared obefazimod 25 mg and 50 mg once daily with placebo for 8 weeks, with adverse events collected for up to 12 weeks. It has no active comparator, and the durability of response is assessed only in the separate ABTECT Maintenance trial, which enrolled Week 8 responders from both induction trials.
- Sources of the results: the results come from the ClinicalTrials.gov posting (first posted September 10, 2026), congress abstracts and posters, and company press releases and filings. The counts differ between sources: the registry lists 639 participants enrolled, the participant flow starts with 318, 161, and 160 by arm, and the Full Analysis Set holds 636, because one participant randomized to 25 mg and two randomized to placebo were never dosed.
- Placebo group and background therapy: randomization was 2:1:1, so the placebo arm holds 158 participants, of whom 4 (2.5%) reached clinical remission at Week 8. Stable oral 5-ASA and oral corticosteroids were allowed, and the protocol states that such background therapy “may be partially effective at controlling UC symptoms”.
- Population: participants were 16 years or older (18 or older in the EU, the EEA, and Ukraine) with a modified Mayo Score of 5 or more and a centrally read endoscopic subscore of 2 or 3. Isolated proctitis, primary sclerosing cholangitis, creatinine clearance below 60 mL/min, QT prolongation, and HIV infection were exclusions. Of the 636 participants analyzed, 288 (45.3%) had a prior inadequate response to an advanced therapy and 52 had a prior inadequate response to a JAK inhibitor; 48 were 65 years or older, 10 were Black or African American, and 166 were Asian. The registry lists 264 locations.
- Endpoints for two regulators: the FDA primary endpoint is clinical remission by the modified Mayo Score; for the EMA, endoscopic improvement and symptomatic remission are co-primary endpoints, and symptomatic remission was not multiplicity controlled under the FDA testing scheme. The Form 20-F describes the primary endpoint as requiring a stool frequency subscore “not greater than baseline”, a condition the registry and protocol definitions do not state.
- Statistical reporting: the posted protocol omits the assumed treatment difference, power, and placebo remission rate behind the sample size of 612 (“difference of at least” is followed by no value). The pooled ABTECT-1 and ABTECT-2 analyses, including the pooled subgroup analyses, report nominal p-values, and the analysis by disease extent is post hoc. Subgroups are small: among participants with prior advanced therapy inadequate response, 6 of 70 (8.6%) receiving 25 mg and 1 of 69 (1.4%) receiving placebo reached clinical remission (p=0.0556).
- Safety reporting: serious adverse events occurred in 14 of 318 participants (4.40%) receiving 50 mg, 1 of 160 (0.63%) receiving 25 mg, and 3 of 158 (1.90%) receiving placebo; events in the 50 mg arm included one myocardial infarction, one acute pancreatitis, one pancreatitis, and one stage I prostate cancer. Figures differ between company sources: the rate of discontinuation for headache is given as “0%–1.6%” in the UEG Week 2025 abstract and “0-1.1%” in the integrated safety abstract, and pooled headache with 50 mg as 24.1% in a press release and 23.3% (148 of 636) in the integrated safety poster.

Source: [ClinicalTrials.gov NCT05507203](https://clinicaltrials.gov/study/NCT05507203); [ClinicalTrials.gov NCT05507203 results](https://clinicaltrials.gov/study/NCT05507203?tab=results); [Abivax ABX464-105 protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/03/NCT05507203/Prot_000.pdf); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download); [Heeren et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.097/8432669); [D'Haens et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.138/8432748); [Seidler et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/Supplement_1/jjaf231.893/8433392); [Dulai et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/abivax-poster-favorable-safety-acg-2026.pdf); [Abivax press release, UEG late-breaking safety data (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
